All In Biotech

Drug Trial Radar · NCT03536767

Open-Label Study of AG10 in Patients With Cardiomyopathy

An Open-Label Extension and Safety Monitoring Study of Patients With Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

47

Actual

Start

Aug 8, 2018

Primary completion

Sep 15, 2025

Study completion Sep 15, 2025

Sponsor

Sponsor type
Industry
First posted
May 25, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of acoramidis administered on a background of stable heart failure therapy.

Conditions

  • Amyloid Cardiomyopathy

Interventions

  • AcoramidisDrug

    Acoramidis 800 mg twice daily, oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Summary of Treatment-Emergent Adverse Events.Time frame: From the first dose of study drug until 30 days after the last dose of study drug. (Maximum exposure reported 84.1 months).

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California

  • Stanford University

    Stanford, California

  • Yale University

    New Haven, Connecticut

  • Northwestern University

    Chicago, Illinois

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Columbia University

    New York, New York

  • Oregon Health & Science University

    Portland, Oregon

  • Medical University of South Carolina

    Charleston, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.